|
LIVE WEBINARS: January 11 & February 22, 2021
Cancer Conference Update: What Happened at the 2020 San Antonio Breast Cancer SymposiumManagement of Triple-Negative Breast CancerResearch To Practice (RTP) is pleased to offer these complimentary 1-hour CME-certified virtual sessions on 2 different dates. Both events moderated by Dr Neil Love and feature a renowned clinical investigator with expertise in triple-negative breast cancer. The program format will be conversational, incorporating cases from community practice and a blend of didactic presentation, interactive polling of attendees and follow-up audience Q&A. All events moderated by Monday, January 11, 2021 from 5:00 PM – 6:00 PM Eastern Time
P Kelly Marcom, MD
Director, Breast Oncology Program Professor of Medicine Duke Cancer Institute Durham, North Carolina Monday, February 22, 2021 from 5:00 PM – 6:00 PM Eastern Time
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research Baylor University Medical Center Director, Breast Cancer Research Program Texas Oncology US Oncology Dallas, Texas These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Genentech, a member of the Roche Group, and Merck. Topics to Be Discussed MODULE 1: Optimal Integration of Immune Checkpoint Inhibitors into the Management of Metastatic Triple-Negative Breast Cancer (mTNBC)
MODULE 2: Novel Applications of Immune Checkpoint Inhibitors for Patients with Early TNBC
MODULE 3: Current and Future Role of PARP Inhibitors for Patients with TNBC and a BRCA Mutation
MODULE 4: Current and Future Management of PD-L1-Negative mTNBC
Target Audience
CME Credit Form Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Content Validation and Disclosures Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Marcom — Advisory Committee: Immunomedics Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, GlycoMimetics Inc, Novartis, Takeda Oncology, Verily; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group. Dr O’Shaughnessy — Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Exact Sciences Inc, Genentech, a member of the Roche Group, Grail Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Jounce Therapeutics, Lilly, Merck, Myriad Genetic Laboratories Inc, Novartis, Odonate Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seagen Inc, Syndax Pharmaceuticals Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Lilly, Novartis, Seagen Inc.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Genentech, a member of the Roche Group, and Merck. |